* U.S. FDA grants priority review of Xarelto® (rivaroxaban) SNDA for a 10 mg dose to reduce the risk of recurrent venous thromboembolism (VTE)

* Janssen - ‍U.S. Food and Drug Administration accepted for priority review a supplemental new drug application (SNDA) for Xarelto (rivaroxaban)​

* Janssen - ‍SNDA is to include 10 mg once-daily dose for reducing risk of VTE after atleast 6 months of standard anticoagulant therapy​‍​​ Source text for Eikon: Further company coverage: